Stock CTIX CELLCEUTIX
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases CELLCEUTIX OTC Bulletin Board

Equities

CTIX

US15115V1017

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for CELLCEUTIX
Feb. 01 Innovation Pharmaceuticals Inc. Announces Resignation of Board Members CI
2023 Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
AQ
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases
AQ
Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing
AQ
Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications
AQ
Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers
AQ
Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission
AQ
INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement
AQ
INNOVATION PHARMACEUTICALS INC. : Other Events (form 8-K)
AQ
Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis
AQ
Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal Keratitis
AQ
Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family
AQ
Scientific Poster on Innovation Pharmaceuticals Brilacidin to be Presented at 2022 Chemical and Biological Defense Science & Technology Conference
AQ
INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Innovation Pharmaceuticals - NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy 'Game-Changing Breakthrough'
AQ
NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy "Game-Changing Breakthrough"
AQ
Innovation Pharmaceuticals Announces Publication of Scientific Article on the Antifungal Activity of Brilacidin
AQ
INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
New In Vitro Data Supporting the Broad-Spectrum Antiviral Activity of Innovation Pharmaceuticals Brilacidin Presented at 2022 Military Health System Research Symposium
AQ
Innovation Pharmaceuticals Investment in BT BeaMedical Helping Advance New Surgical Laser Platform
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IPIX Stock
  4. CTIX Stock
  5. News CELLCEUTIX
  6. Press Releases